Biological and Clinical Efficacy of Shingrix in Patients With CLL

Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Study ID
NCT06364033
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • serologic response evaluation — BIOLOGICAL
    Blood samples collection

Study Details

This is a biological study. Patients who are eligible to receive Shingrix through the Italian National Health System will be invited to participate in the study. According to AIFA indication, the two doses of vaccine will be administered 4-8 weeks apart. Blood samples will be collected prior to the first vaccine dose (i.e. within the time frame of 3 months prior to the first dose) and 1, 6, 12, 24 and 36 months after the second vaccine dose to evaluate the serological response of Shingrix.

Key Dates

First listed
Apr 15, 2024
Start date
Aug 31, 2024
Status verified
May 2024
Primary completion
Nov 30, 2025
Completion
Oct 31, 2028

Study Design

Enrollment
312 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Primary Outcome Measure

Serologic response evaluation [ Time Frame: at 1 month ]

Central Contacts

Find similar trials

Nationwide
Leukemia (other) trialsOncology trialsBlood cancer trials

Related Studies